Virogin Biotech is an antineoplastic drug developer.
Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment.By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 24, 2021 | Series D | $120M | 1 |
|
— | Detail |
Sep 28, 2020 | Series C | $62M | 2 | — | — | Detail |
Jun 7, 2020 | Series B | — | 1 | — | — | Detail |
Feb 28, 2017 | Series A | $5M | 2 | — | — | Detail |
Mar 21, 2016 | Series A | $7M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
|
Yes | Series D |
|
Yes | Seed |
|
— | Series C |
![]() |
— | Series C |
|
— | Series B |
|
— | Series A |